Alnylam Pharmaceuticals, Inc. reiterated earnings guidance for the full year 2024. For the period, the company expects combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO to be $1,400 million to $1,500 million and net revenues from collaborations and royalties to be $325 million to $425 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
148.5 USD | -1.18% | +0.52% | -22.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.33% | 19B | |
+41.37% | 54.04B | |
+43.57% | 41.96B | |
-1.29% | 41.92B | |
-7.59% | 28.35B | |
+12.44% | 26.35B | |
+7.83% | 13B | |
+28.88% | 12.28B | |
+24.94% | 12.19B | |
-6.39% | 11.49B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024